GSK: FDA Accepts Application To Review Expanded Use Of RSV Vaccine, Arexvy

GSK plc's Arexvy respiratory syncytial virus (RSV) vaccine has had its application accepted by the FDA for an expanded indication to adults aged 18-49 who are at increased risk, building on its current US approval for individuals 60+ and 50-59 at elevated risk. A regulatory decision from the FDA is anticipated in the first half of 2026. This move signifies GSK's strategy to broaden the vaccine's market reach, as the company simultaneously pursues expanded indications for Arexvy across other global markets, including the European Economic Area and Japan.

Analysis

GSK has achieved a positive regulatory milestone with the FDA's acceptance for review of its application to expand the indication for its RSV vaccine, Arexvy. This proposed expansion targets a new demographic of at-risk adults aged 18-49, which would significantly broaden the vaccine's addressable market beyond the currently approved cohorts of individuals 60+ and at-risk adults aged 50-59. While this development supports GSK's strategy to maximize the commercial potential of a key asset, the projected regulatory decision timeline in the first half of 2026 positions this as a long-term catalyst. The low market impact score of 0.3 reflects this extended timeline, suggesting minimal immediate impact on valuation. The concurrent pursuit of expanded indications in Europe and Japan further underscores a deliberate global strategy to entrench Arexvy's market position.

Key Decisions for Investors

• Investors should view this as a positive long-term development for GSK's vaccine portfolio, but factor in the distant H1 2026 timeline for a potential FDA decision, which limits near-term impact.
• Monitor for any clinical data releases or regulatory feedback concerning this application, as it represents a significant potential expansion of Arexvy's total addressable market.
• Consider this a de-risking event in the regulatory pathway, but full valuation credit for the expanded indication should be withheld pending final FDA approval and competitive landscape analysis.